| Literature DB >> 26852389 |
Suvi Taponen1, Suvi Nykäsenoja2, Tarja Pohjanvirta3, Anna Pitkälä4, Satu Pyörälä5.
Abstract
BACKGROUND: Coagulase-negative staphylococci (CoNS) are the most common bovine mastitis causing bacteria in many countries. It is known that resistance for antimicrobials is in general more common in CoNS than in Staphylococcus aureus but little is known about the antimicrobial resistance of specific CoNS species. In this study, 400 CoNS isolates from bovine mastitic milk samples were identified to species level using ribotyping and MALDI-TOF MS, and their antimicrobial susceptibility was determined using a commercially available microdilution system. The results were interpreted according to the epidemiological cut-off values by the European Committee on Antimicrobial Susceptibility testing.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26852389 PMCID: PMC4744398 DOI: 10.1186/s13028-016-0193-8
Source DB: PubMed Journal: Acta Vet Scand ISSN: 0044-605X Impact factor: 1.695
Distribution of coagulase-negative Staphylococcus species isolated in bovine milk samples in 2001 (dataset 1) and 2012 (dataset 2)
| CNS species | 2001 | 2012 | In total | |||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
|
| 7 | 2.2 | 3 | 3.4 | 10 | 2.5 |
|
| 1 | 0.3 | 1 | 1.1 | 2 | 0.5 |
|
| 48 | 15.4 | 6 | 6.8 | 54 | 13.5 |
|
| 7 | 2.2 | 5 | 5.7 | 12 | 3.0 |
|
| 78 | 25.0 | 27 | 30.7 | 105 | 26.3 |
|
| 3 | 1.0 | 0 | 0 | 3 | 0.8 |
|
| 37 | 11.9 | 5 | 5.7 | 42 | 10.5 |
|
| 4 | 1.3 | 1 | 1.1 | 5 | 1.3 |
|
| 0 | 0 | 3 | 3.4 | 3 | 0.75 |
|
| 2 | 0.6 | 0 | 0 | 2 | 0.5 |
|
| 2 | 0.6 | 1 | 1.1 | 3 | 0.8 |
|
| 2 | 0.6 | 1 | 1.1 | 3 | 0.8 |
|
| 78 | 25.0 | 30 | 34.1 | 108 | 27.0 |
|
| 32 | 10.3 | 1 | 1.1 | 33 | 8.3 |
|
| 8 | 2.6 | 2 | 2.3 | 10 | 2.5 |
|
| 3 | 1.0 | 2 | 2.3 | 5 | 1.3 |
| In total | 312 | 88 | 400 | |||
The material consisted of CoNS isolates from two studies, Pitkälä et al. [2] (dataset 1) and Finnish veterinary antimicrobial resistance monitoring program 2010–2012 [18] (dataset 2). In dataset 1 all quarters of cows were sampled in a mastitis survey, in dataset 2 samples originated from quarters with mastitis
In vitro susceptibility to 14 antimicrobials of S. chromogenes, S. epidermidis, S. haemolyticus and S. simulans isolated in bovine milk samples from dataset 1 (2001)
| Antimicrobial | Organism | N | N (%) > ECOFF | MIC mg/l, % of isolates | ECOFFa | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benzylpenicillin | ≤ |
|
|
|
|
|
|
| ≥ |
| |||||||
|
| 48 | 14 (29.2) | 68.8 | 2.1 | 4.2 | 6.3 | 12.5 | 6.3 | |||||||||
|
| 78 | 58 (74.4) | 23.1 | 2.6 | 6.4 | 9.0 | 12.8 | 15.4 | 9.0 | 11.5 | 10.3 | ||||||
|
| 37 | 24 (64.9) | 32.4 | 2.7 | 16.2 | 27.0 | 13.5 | 5.4 | 2.7 | ||||||||
|
| 78 | 3 (3.8) | 93.6 | 2.6 | 2.6 | 1.3 | |||||||||||
| Oxacillin | ≤ |
|
|
| ≥ |
| |||||||||||
|
| 48 | 19 (39.6) | 20.8 | 39.6 | 37.5 | 2.1 | |||||||||||
|
| 78 | 27 (34.6) | 38.5 | 26.9 | 15.4 | 6.4 | 12.8 | ||||||||||
|
| 37 | 10 (27.0) | 32.4 | 40.5 | 24.3 | 2.7 | |||||||||||
|
| 78 | 15 (19.2) | 38.5 | 42.3 | 19.2 | ||||||||||||
| Cephalothin | ≤ |
|
|
|
|
| ≥ |
| |||||||||
|
| 48 | 22.9 | 70.8 | 6.3 | |||||||||||||
|
| 78 | 21.8 | 55.1 | 9.0 | 14.1 | ||||||||||||
|
| 37 | 10.8 | 67.6 | 21.6 | |||||||||||||
|
| 78 | 6.4 | 56.4 | 37.2 | |||||||||||||
| Streptomycin | ≤ |
|
|
|
|
|
| ≥ |
| ||||||||
|
| 48 | 81.3 | 14.6 | 4.2 | |||||||||||||
|
| 78 | 17 (21.8) | 71.8 | 2.6 | 2.6 | 1.3 | 2.6 | 5.1 | 6.4 | 7.7 | |||||||
|
| 37 | 97.3 | 2.7 | ||||||||||||||
|
| 78 | 1 (1.3) | 68.2 | 19.2 | 5.1 | 5.1 | 1.3 | ||||||||||
| Neomycin | ≤ |
|
|
|
|
| ≥ |
| |||||||||
|
| 48 | 97.9 | 2.1 | ||||||||||||||
|
| 78 | 89.7 | 1.3 | 3.8 | 3.8 | 1.3 | |||||||||||
|
| 37 | 100.0 | |||||||||||||||
|
| 78 | 100.0 | |||||||||||||||
| Gentamicin | ≤ |
|
|
|
|
| ≥ |
| |||||||||
|
| 48 | 95.8 | 4.2 | ||||||||||||||
|
| 78 | 100.0 | |||||||||||||||
|
| 37 | 100.0 | |||||||||||||||
|
| 78 | 2 (2.6) | 88.5 | 9.0 | 2.6 | ||||||||||||
| Clindamycin | ≤ |
|
| ≥ |
| ||||||||||||
|
| 48 | 100.0 | |||||||||||||||
|
| 78 | 100.0 | |||||||||||||||
|
| 37 | 97.3 | 2.7 | ||||||||||||||
|
| 78 | 100.0 | |||||||||||||||
| Erythromycin | ≤ |
|
|
| ≥ |
| |||||||||||
|
| 48 | 2 (4.2) | 95.8 | 4.2 | |||||||||||||
|
| 78 | 11 (14.1) | 84.6 | 1.3 | 14.1 | ||||||||||||
|
| 37 | 1 (2.7) | 94.6 | 2.7 | 2.7 | ||||||||||||
|
| 78 | 100.0 | |||||||||||||||
| Chloramphenicol | ≤ |
|
|
| ≥ |
| |||||||||||
|
| 48 | 4.2 | 77.1 | 18.8 | |||||||||||||
|
| 78 | 2 (2.6) | 1.3 | 87.2 | 1.3 | 7.7 | 2.6 | ||||||||||
|
| 37 | 10.8 | 86.5 | 2.7 | |||||||||||||
|
| 78 | 3.8 | 47.4 | 46.2 | 2.6 | ||||||||||||
| Tetracycline | ≤ |
|
|
|
|
|
|
| ≥ |
| |||||||
|
| 48 | 3 (6.2) | 87.5 | 6.3 | 2.1 | 4.2 | |||||||||||
|
| 78 | 36 (46.2) | 47.4 | 6.4 | 7.7 | 20.5 | 2.6 | 1.3 | 3.8 | 10.3 | |||||||
|
| 37 | 75.7 | 24.3 | ||||||||||||||
|
| 78 | 4 (5.1) | 21.8 | 73.1 | 2.6 | 1.3 | 1.3 | ||||||||||
| Trimetoprim-sulfamethoxazole | ≤ |
|
|
|
|
| ≥ |
| |||||||||
|
| 48 | 5 (10.4) | 75.0 | 14.6 | 4.2 | 2.1 | 2.1 | 2.1 | |||||||||
|
| 78 | 7 (9.0) | 73.1 | 17.9 | 5.1 | 2.6 | 1.3 | ||||||||||
|
| 37 | 89.2 | 10.8 | ||||||||||||||
|
| 78 | 6 (7.7) | 29.5 | 62.8 | 6.1 | 2.6 | |||||||||||
| Vancomycin | ≤ |
|
|
|
|
| ≥ |
| |||||||||
|
| 48 | 83.3 | 16.7 | ||||||||||||||
|
| 78 | 26.9 | 73.1 | ||||||||||||||
|
| 37 | 81.1 | 18.9 | ||||||||||||||
|
| 78 | 1 (1.3) | 91.0 | 6.4 | 1.3 | 1.3 | |||||||||||
| Virginiamycin | ≤ |
|
|
| ≥ |
| |||||||||||
|
| 48 | 2 (4.2) | 25.0 | 70.8 | 4.2 | ||||||||||||
|
| 78 | 1 (1.3) | 65.4 | 33.3 | 1.3 | ||||||||||||
|
| 37 | 1 (2.7) | 37.8 | 59.5 | 2.7 | ||||||||||||
|
| 78 | 2 (2.6) | 15.4 | 82.1 | 1.3 | 1.3 | |||||||||||
| Avilamycin | ≤ |
|
|
|
|
|
| ≥ |
| ||||||||
|
| 48 | 27.1 | 54.2 | 18.8 | |||||||||||||
|
| 78 | 29.5 | 65.4 | 5.1 | |||||||||||||
|
| 37 | 16.2 | 59.5 | 21.6 | 2.7 | ||||||||||||
|
| 78 | 1.3 | 1.3 | 11.5 | 37.2 | 33.3 | 15.4 | ||||||||||
In this dataset, all quarters of cows were sampled in a mastitis survey [2]
ND not determined
aCurrent (March 2015) EUCAST epidemiological cut-off (ECOFF) values (mg/l) for CNS were used to define resistant isolates. If ECOFF for CNS was not available, the value for S. aureus was used. For virginiamycin, ECOFF for S. intermedius was used
bECOFF for S. aureus
cECOFF for S. intermedius
In vitro susceptibility to 17 antimicrobials of S. chromogenes, S. epidermidis, S. haemolyticus and S. simulans isolated in bovine milk samples from dataset 2 (2012)
| Antimicrobial | Organism | N | N (%) > ECOFF | MIC mg/l, % of isolates | ECOFFa | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benzylpenicillin | ≤ |
|
|
|
|
|
|
| ≥ |
| |||||||
|
| 6 | 1 (16.7) | 33.3 | 50.0 | 16.7 | ||||||||||||
|
| 27 | 20 (74.1) | 18.5 | 3.7 | 3.7 | 11.1 | 7.4 | 18.5 | 7.4 | 22.2 | 7.4 | ||||||
|
| 5 | 2 (40.0) | 20.0 | 40.0 | 40.0 | ||||||||||||
|
| 30 | 2 (6.6) | 63.3 | 30.0 | 3.3 | 3.3 | |||||||||||
| Oxacillin | ≤ |
|
|
|
|
|
|
| ≥ |
| |||||||
|
| 6 | 16.7 | 16.7 | 66.7 | |||||||||||||
|
| 27 | 4 (14.8) | 3.7 | 66.7 | 14.8 | 3.7 | 3.7 | 7.4 | |||||||||
|
| 5 | 80.0 | 20.0 | ||||||||||||||
|
| 30 | 2 (6.6) | 6.7 | 36.7 | 50.0 | 3.3 | 3.3 | ||||||||||
| Cephalothin | ≤ |
|
|
|
|
|
| ≥ |
| ||||||||
|
| 6 | 50.0 | 50.0 | ||||||||||||||
|
| 27 | 3.7 | 40.7 | 37.0 | 11.1 | 7.4 | |||||||||||
|
| 5 | 20.0 | 40.0 | 40.0 | |||||||||||||
|
| 30 | 6.7 | 70.0 | 23.3 | |||||||||||||
| Streptomycin | ≤ |
|
|
| ≥ |
| |||||||||||
|
| 6 | 83.3 | 16.7 | ||||||||||||||
|
| 27 | 2 (7.4) | 81.5 | 11.1 | 3.7 | 3.7 | |||||||||||
|
| 5 | 100.0 | |||||||||||||||
|
| 30 | 1 (3.3) | 73.3 | 20.0 | 3.3 | 3.3 | |||||||||||
| Neomycin | ≤ |
|
|
| ≥ |
| |||||||||||
|
| 6 | 100.0 | |||||||||||||||
|
| 27 | 96.3 | 3.7 | ||||||||||||||
|
| 5 | 100.0 | |||||||||||||||
|
| 30 | 100.0 | |||||||||||||||
| Gentamicin | ≤ |
|
|
|
| ≥ |
| ||||||||||
|
| 6 | 100.0 | |||||||||||||||
|
| 27 | 100.0 | |||||||||||||||
|
| 5 | 100.0 | |||||||||||||||
|
| 30 | 1 (3.3) | 96.7 | 3.3 | |||||||||||||
| Clindamycin | ≤ |
|
|
|
| ≥ |
| ||||||||||
|
| 6 | 100.0 | |||||||||||||||
|
| 27 | 100.0 | |||||||||||||||
|
| 5 | 100.0 | |||||||||||||||
|
| 30 | 3 (10.0) | 90.0 | 10.0 | |||||||||||||
| Erythromycin | ≤ |
|
|
|
| ≥ |
| ||||||||||
|
| 6 | 83.3 | 16.7 | ||||||||||||||
|
| 27 | 25.9 | 70.4 | 3.7 | |||||||||||||
|
| 5 | 20.0 | 80.0 | ||||||||||||||
|
| 30 | 10.0 | 86.7 | 3.3 | |||||||||||||
| Chloramphenicol | ≤ |
|
|
| ≥ |
| |||||||||||
|
| 6 | 33.3 | 66.7 | ||||||||||||||
|
| 27 | 92.6 | 7.4 | ||||||||||||||
|
| 5 | 100.0 | |||||||||||||||
|
| 30 | 76.7 | 23.3 | ||||||||||||||
| Tetracycline | ≤ |
|
|
|
|
|
|
| ≥ |
| |||||||
|
| 6 | 100.0 | |||||||||||||||
|
| 27 | 7 (25.9) | 66.7 | 7.4 | 18.5 | 7.4 | |||||||||||
|
| 5 | 100.0 | |||||||||||||||
|
| 30 | 2 (6.7) | 90.0 | 3.3 | 6.7 | ||||||||||||
| Trimetoprim-sulfamethoxazole | ≤ |
|
| ≥ |
| ||||||||||||
|
| 6 | 100.0 | |||||||||||||||
|
| 27 | 2 (7.4) | 92.6 | 7.4 | |||||||||||||
|
| 5 | 100.0 | |||||||||||||||
|
| 30 | 100.0 | |||||||||||||||
| Cefoxitin | ≤ |
|
|
|
|
|
|
| ≥ |
| |||||||
|
| 6 | 83.3 | 16.7 | ||||||||||||||
|
| 27 | 5 (18.5) | 3.7 | 55.6 | 22.2 | 7.4 | 3.7 | 7.4 | |||||||||
|
| 5 | 40.0 | 60.0 | ||||||||||||||
|
| 30 | 3.3 | 80.0 | 16.7 | |||||||||||||
| Kanamycin | ≤ |
|
|
|
|
|
|
|
| ≥ |
| ||||||
|
| 6 | 33.3 | 66.7 | ||||||||||||||
|
| 27 | 2 (7.4) | 18.5 | 48.1 | 25.9 | 3.7 | 3.7 | ||||||||||
|
| 5 | 80.0 | 20.0 | ||||||||||||||
|
| 30 | 30.0 | 40.0 | 30.0 | |||||||||||||
| Florphenicol | ≤ |
|
| ≥ |
| ||||||||||||
|
| 6 | 50.0 | 50.0 | ||||||||||||||
|
| 27 | 48.1 | 51.9 | ||||||||||||||
|
| 5 | 60.0 | 40.0 | ||||||||||||||
|
| 30 | 10.0 | 86.7 | 3.3 | |||||||||||||
| Trimetoprim | ≤ |
|
|
|
|
|
| ≥ |
| ||||||||
|
| 6 | 50.0 | 50 | ||||||||||||||
|
| 27 | 4 (14.8) | 11.1 | 44.4 | 29,6 | 3.7 | 3.7 | 7.4 | |||||||||
|
| 5 | 4 (80.0) | 20.0 | 40.0 | 40.0 | ||||||||||||
|
| 30 | 29 (96.7) | 3.3 | 6.7 | 36.7 | 50.0 | 3.3 | ||||||||||
| Ciprofloxacin | ≤ |
|
|
| ≥ |
| |||||||||||
|
| 6 | 100.0 | |||||||||||||||
|
| 27 | 14.8 | 81.5 | 3.7 | |||||||||||||
|
| 5 | 80.0 | 20.0 | ||||||||||||||
|
| 30 | 50.0 | 50.0 | ||||||||||||||
| Fusidic acid | ≤ |
|
|
|
|
|
|
| ≥ |
| |||||||
|
| 6 | 1 (16.7) | 66.7 | 16.7 | 16.7 | ||||||||||||
|
| 27 | 10 (37.0) | 3.7 | 59.3 | 25.9 | 3.7 | 7.4 | ||||||||||
|
| 5 | 100.0 | |||||||||||||||
|
| 30 | 10 (33.3) | 6.7 | 60.0 | 33.3 | ||||||||||||
In this dataset, samples were collected in the Finnish veterinary antimicrobial resistance monitoring program 2010-2012 [18] and they originated from quarters with mastitis
aCurrent (March 2015) EUCAST epidemiological cut-off (ECOFF) values (mg/l) for CNS were used to define resistant isolates. If ECOFF for CNS was not available, the value for S. aureus was used. For virginiamycin, ECOFF for S. intermedius was used
bECOFF for S. aureus